Inotiv, Inc. Common Stock
Symbol: NOTV (NASDAQ)
Company Description:
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.
- Today's Open: $1.442
- Today's High: $1.485
- Today's Low: $1.426
- Today's Volume: 57.65K
- Yesterday Close: $1.44
- Yesterday High: $1.55
- Yesterday Low: $1.41
- Yesterday Volume: 587.33K
- Last Min Volume: 1.27K
- Last Min High: $1.435
- Last Min Low: $1.427
- Last Min VWAP: $1.43185
- Name: Inotiv, Inc. Common Stock
- Website: https://www.inotivco.com
- Listed Date: 1997-11-25
- Location: WEST LAFAYETTE, IN
- Market Status: Active
- CIK Number: 0000720154
- SIC Code: 8731
- SIC description: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
- Market Cap: $47.75M
- Round Lot: 100
- Outstanding Shares: 34.36M
- Asset Type: CS
Filing Date | Filing Type | Format |
---|---|---|
2025-09-11 | EFFECT | View |
2025-09-04 | 4 | View |
2025-09-02 | 144 | View |
2025-08-29 | S-3 | View |
2025-08-18 | 8-K | View |
2025-08-07 | 10-Q | View |
2025-08-07 | 8-K/A | View |
2025-08-06 | 8-K | View |
2025-08-04 | 4 | View |
2025-07-18 | 424B7 | View |
2025-07-03 | 4 | View |
2025-06-04 | 4 | View |
2025-06-04 | 8-K | View |
2025-06-02 | 144 | View |
2025-05-29 | 8-K | View |
2025-05-08 | 10-Q | View |
2025-05-07 | 8-K | View |
2025-04-02 | 4 | View |
2025-04-01 | 144 | View |
2025-03-18 | 4 | View |